AU2008310312B2 - Method of eliciting an immune response against pandemic influenza virus - Google Patents

Method of eliciting an immune response against pandemic influenza virus Download PDF

Info

Publication number
AU2008310312B2
AU2008310312B2 AU2008310312A AU2008310312A AU2008310312B2 AU 2008310312 B2 AU2008310312 B2 AU 2008310312B2 AU 2008310312 A AU2008310312 A AU 2008310312A AU 2008310312 A AU2008310312 A AU 2008310312A AU 2008310312 B2 AU2008310312 B2 AU 2008310312B2
Authority
AU
Australia
Prior art keywords
influenza
immunogen
adjuvant
subtype
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008310312A
Other languages
English (en)
Other versions
AU2008310312A1 (en
Inventor
Martin Pearse
Steve Rockman
David Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of AU2008310312A1 publication Critical patent/AU2008310312A1/en
Application granted granted Critical
Publication of AU2008310312B2 publication Critical patent/AU2008310312B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008310312A 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus Active AU2008310312B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97957207P 2007-10-12 2007-10-12
US60/979,572 2007-10-12
PCT/AU2008/001500 WO2009046497A1 (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Publications (2)

Publication Number Publication Date
AU2008310312A1 AU2008310312A1 (en) 2009-04-16
AU2008310312B2 true AU2008310312B2 (en) 2013-12-19

Family

ID=40548886

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008310312A Active AU2008310312B2 (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Country Status (10)

Country Link
US (1) US8999353B2 (https=)
EP (1) EP2195019A4 (https=)
JP (1) JP2011500514A (https=)
KR (1) KR20100082825A (https=)
CN (1) CN101820904A (https=)
AU (1) AU2008310312B2 (https=)
CA (1) CA2700937C (https=)
NZ (1) NZ583377A (https=)
SG (1) SG185294A1 (https=)
WO (1) WO2009046497A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595653B1 (en) 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
US9524531B2 (en) * 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100110A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Novel composition
WO2008025095A1 (en) * 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323733A1 (en) 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
AU2001251316A1 (en) 2000-04-04 2001-10-15 Antigenics Inc. Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
US20040081654A1 (en) 2000-06-16 2004-04-29 Schryvers Anthony B Use of plant oil-bodies in vaccine delivery systems
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20030190333A1 (en) * 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
AU2005244128B2 (en) 2004-05-07 2009-06-25 President And Fellows Of Harvard College Pulmonary malarial vaccine
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100110A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Novel composition
WO2008025095A1 (en) * 2006-09-01 2008-03-06 Csl Limited Method of eliciting or inducing an immune response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COULTER, A., et al., "Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine," Vaccine, 2003, Vol. 21, page 946-949. *
ENNIS, F. A., et al., "Augmentation of Human Influenza A Virus-Specific Cytotoxic T Lymphocyte Memory by Influenza Vaccine and Adjuvanted Carriers (ISCOMS)," Virology, 1999, Vol.259, pages 256-261. *
RIMMELZWAAN, G.F., et al., "A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOMTM vaccines and conventional vaccines," Vaccine, 2001, Vol. 19, pg 1180-1187 *
SCHEERLINCK, J.-P. Y., et al., "Local immune responses following nasal delivery of an adjuvanted influenza vaccine," Vaccine, 2006, Vol. 24, pages 3929-3936. *
WINDON, R.G., et al., "Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX®," Vaccine, 2001, Vol. 20, pages 490-497. *

Also Published As

Publication number Publication date
KR20100082825A (ko) 2010-07-20
JP2011500514A (ja) 2011-01-06
CA2700937A1 (en) 2009-04-16
US8999353B2 (en) 2015-04-07
CA2700937C (en) 2017-05-09
EP2195019A4 (en) 2012-02-15
NZ583377A (en) 2013-11-29
WO2009046497A1 (en) 2009-04-16
US20100291146A1 (en) 2010-11-18
CN101820904A (zh) 2010-09-01
EP2195019A1 (en) 2010-06-16
SG185294A1 (en) 2012-11-29
AU2008310312A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US11564984B2 (en) Influenza vaccine
JP5869744B2 (ja) Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
Carter et al. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted)[Prepandrix™] A review of its use as an active immunization against influenza A subtype H5N1 virus
Ellebedy et al. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets
EP2422810B1 (en) Influenza vaccine
EP2015774A1 (en) Influenza virus vaccine
Kim et al. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection
AU2008310312B2 (en) Method of eliciting an immune response against pandemic influenza virus
CN101808659A (zh) 灭活的流感疫苗
Heldens et al. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits
Oxford et al. Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic
US20240335522A1 (en) Multivalent pan-influenza vaccine
Hashimoto et al. A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
CA2583555C (en) Influenza vaccine
Oxford et al. History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine
Lu Development of Pre-pandemic Influenza Vaccines against Highly Pathogenic H5 Strains
Sweeter Human IGG and IGE antibody response to low-dose intradermal versus standard dose intramuscular influenza vaccination
Ebensen et al. Preclinical Animal Models for Developing Vaccines Against Influenza Infection for the Young and the Elderly
BRPI0609516B1 (pt) uso de um vírus de influenza ou preparação antigênica do mesmo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)